Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Treatments for ALS, and why breathing support matters most

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

The honest summary is that no treatment stops or reverses ALS, and that several things meaningfully change how long and how well people live.

The interventions with the largest effect are not drugs, which is worth knowing early, because they are the ones most often started later than they should be.

Related pages: ALS (amyotrophic lateral sclerosis)

The bottom line

What we know
  • Riluzole and edaravone slow progression modestly.
  • Tofersen targets ALS caused by SOD1 mutations, a small proportion of cases.
  • Non-invasive ventilation prolongs survival and improves quality of life.
  • Care in a multidisciplinary ALS clinic is associated with longer survival.
What is still open
  • Why drug effects in ALS have been so consistently modest.
  • Which combinations or earlier timings might do better, which trials are testing.

The story, step by step

  1. 1. The drugs ()
  2. 2. Breathing support ()
  3. 3. The clinic ()
  4. 4. Symptoms ()
  5. 5. Planning ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

What they do, honestly

Review of many studies

What happens

Three disease-modifying treatments are available in at least some countries, and the scale of benefit should be stated plainly.

What the research shows

  • Riluzole, approved in 1995, reduces glutamate release. In trials it extended survival by around two to three months on average. It is still the standard first treatment.
  • Edaravone, a free radical scavenger, was approved in the US in 2017 based on a trial in a selected group of people early in the disease. The European Medicines Agency declined to approve it, considering the evidence insufficient. Availability therefore varies by country.
  • Tofersen is given by injection into the spinal fluid for people whose ALS is caused by a SOD1 gene mutation, around 2 percent of all cases. It lowers markers of nerve damage; its main trial did not meet its primary clinical endpoint, and it was approved on that biomarker evidence.
  • Relyvrio, also known as AMX0035, was approved in the US and Canada and then withdrawn in 2024 after a larger trial showed no benefit. Material written before then may still recommend it.
  • Several drugs are in trials. Asking about trial eligibility at diagnosis is reasonable and is often how people access newer treatments.

Why it matters

Stating the size of the benefit matters. People are entitled to decide for themselves whether a few months is worth it, and many do take these drugs.

What's still uncertain

  • Average effects conceal individual variation, and there is no way to know in advance who benefits most.

Read more

Next: Breathing support

Part 2 of 5

The intervention with the biggest effect

Review of many studies

What happens

Non-invasive ventilation has a larger demonstrated effect on survival than any drug in ALS.

What the research shows

  • A machine delivers pressurized air through a mask, usually worn at night at first, supporting breathing muscles that are tiring.
  • In trials it extended survival meaningfully and improved quality of life, particularly in people without severe bulbar involvement.
  • It is started based on breathing tests and symptoms rather than waiting for obvious breathlessness, because the early signs are poor sleep and morning headache.
  • Cough assist devices help clear secretions when the cough is weak, reducing chest infections.
  • Invasive ventilation through a tracheostomy is a separate decision with major implications, and is best discussed well before it might be needed, not during a crisis.

Why it matters

If you take one thing from this page: ask about breathing tests early and start ventilation when it is offered rather than when breathlessness forces it.

What's still uncertain

  • Benefit is less clear in people with severe bulbar weakness, where mask tolerance is poorer.

Read more

Next: The clinic

Part 3 of 5

Why multidisciplinary care counts as treatment

Review of many studies

What happens

Attending a multidisciplinary ALS clinic is associated with longer survival, which puts it in the same category as the drugs.

What the research shows

  • One visit brings together neurology, respiratory care, speech and language therapy, physiotherapy, occupational therapy, dietetics, nursing and social work.
  • That reduces the burden of separate appointments at a time when travel becomes difficult, and means decisions are coordinated.
  • Speech and language therapy covers both communication and safe swallowing, and introduces communication technology before it is urgently needed.
  • Occupational therapy and equipment, from a wrist splint to a wheelchair to home adaptations, preserve independence, and lead times for equipment are often long.
  • Palliative care involvement is about symptom control and planning, and is appropriate from early in the disease rather than at the end. Involving it early is associated with better symptom management, not with giving up.

Why it matters

Early referral is the recurring theme: equipment, communication devices and ventilation all work best when arranged before they are needed.

What's still uncertain

  • Access to specialist clinics is uneven, and travel can itself be a barrier.

Read more

Next: Symptoms

Part 4 of 5

What can actually be relieved

Review of many studies

What happens

A great deal of what makes ALS difficult day to day is treatable, and some of it is under-treated.

What the research shows

  • Cramps: medicines and stretching help, and this is worth raising because it is often not asked about.
  • Spasticity: physiotherapy, stretching, and medicines such as baclofen.
  • Excess saliva and drooling: medicines that reduce saliva, and in some cases botulinum toxin injections.
  • Thick secretions: managed differently from excess saliva, with hydration, nebulizers and cough assist.
  • Pseudobulbar affect, uncontrollable laughing or crying: specific treatments exist and work well.
  • Pain, constipation, anxiety, depression and poor sleep are common and all treatable. None of them is simply part of having ALS.

Why it matters

The phrase worth using with a clinician is: this symptom is affecting my day. Many of these are not asked about routinely.

What's still uncertain

  • Evidence for several symptomatic treatments in ALS specifically is limited and borrowed from other conditions.

Read more

Next: Planning

Part 5 of 5

Decisions that are better made early

Review of many studies

What happens

Several decisions are easier to make with time than under pressure, and making them early preserves the person's own voice in them.

What the research shows

  • Feeding tube placement is safer when done before weight loss and breathing weakness are advanced, which is covered on the nutrition page.
  • Communication technology, including voice banking, recording your own voice while speech is still clear, is best arranged early.
  • Advance care planning, including what someone would and would not want regarding ventilation, lets choices be made calmly and revisited later.
  • These conversations are not about giving up. They are about making sure the person's own preferences are the ones that get followed.
  • ALS organizations provide practical guidance and local support: the ALS Association and the Muscular Dystrophy Association in the US, and equivalents elsewhere.

Why it matters

Voice banking is one of those things nobody mentions until it is too late. It is worth asking about at the first clinic visit.

What's still uncertain

  • Preferences change over time, and plans are meant to be revisited rather than fixed.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.